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The NIH Extracellular RNA Communication Program’s initiative on clinical utility of extracellular RNAs and
therapeutic agents and developing scalable technologies is reviewed here. Background information and details
of the projects are presented. The work has focused on modulation of target cell fate by extracellular vesicles
(EVs) and RNA. Work on plant-derived vesicles is of intense interest, and non-mammalian sources of vesicles
may represent a very promising source for different therapeutic approaches. Retro-viral-like particles are
intriguing. Clearly, EVs share pathways with the assembly machinery of several other viruses, including human
endogenous retrovirals (HERVs), and this convergence may explain the observation of viral-like particles
containing viral proteins and nucleic acid in EVs. Dramatic effect on regeneration of damaged bone marrow,
renal, pulmonary and cardiovascular tissue is demonstrated and discussed. These studies show restoration of
injured cell function and the importance of heterogeneity of different vesicle populations. The potential for
neural regeneration is explored, and the capacity to promote and reverse neoplasia by EVexposure is described.
The tremendous clinical potential of EVs underlies many of these projects, and the importance of regulatory
issues and the necessity of general manufacturing production (GMP) studies for eventual clinical trials are
emphasized. Clinical trials are already being pursued and should expand dramatically in the near future.
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T
he NIH Extracellular RNA Communication Pro-
gram has 5 key initiatives: 1) General reference cata-
logue of extracellular RNAs (exRNA) in bodily
fluids of normal individuals. 2) Defining fundamental
principles of exRNA biogenesis, distribution, uptake and
function and development of molecular tools technologies
and imaging modalities to enable these studies. 3) Identifi-
cation of exRNA biomarkers. 4) Demonstrating the clinical
utility of exRNAs as therapeutic agents and developing
scalable technologies. 5) Developing a community resource,
the exRNA atlas, to provide access to exRNA data,
standardized exRNA protocols and other useful tools.

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This contribution summarizes work on the 4th initiative
on functional effects, clinical utility and to some extent
biomarkers.
The definition of the functional effects and clinical
potential of extracellular vesicles is a rapidly expanding
field. Vesicle effects have now been shown in multiple
domains of cell biology and clinical disease. Vesicles have
in general been considered as either exosomes or micro-
vesicles (1), the first originating from the endosomal
compartment and the latter from the cell membrane.
They were originally defined by size and morphology, but
given significant overlap, it has been suggested that they
simply be termed extracellular vesicles (EVs) (2). They con-
tain proteins, genomic and mitochondrial DNA, lipids,
mRNA and non-coding RNA and can deliver these en-
tities to target cells resulting in changes in cell phenotype
or repair of cell injury (35). Their contents and surface
characteristics vary markedly with the nature of the ori-
ginating cell, the treatment of the originating cells and the
isolation techniques employed, and their biologic effects
vary tremendously with the nature of the impacted target
cell; thus, a prime characteristic is their heterogeneity.
The problems with strict identification of EVs has been
highlighted by a consensus article from the International
Society of Extracellular Vesicles which also put forward
some evolving criteria for indicating that investigators were
working with vesicles (6). A number of descriptions of
changes in cell phenotype after vesicle exposure have been
reported, but it is important to realize that the nature of the
vesicle and its biologic effects are very context dependent.
It is of note that thus far three phase 1 clinical immu-
notherapy trials reporting feasibility and safety of auto-
logous EV therapeutics have been published (7,8), and
4 additional EV-based clinical trials have been registered
at ClinicalTrials.gov. Regulatory criteria for EV-based
therapies are still in evolution.
Extracellular vesicles in therapy and
regenerative medicine
A major interest has been the capacity of EVs to restore
injured tissue in regenerative medicine. Several projects in
the Extracellular RNA Communication Consortium sub-
group focused on exRNA therapy are focused on demon-
strating therapeutic potential of exRNAs and to develop
methods and tools to enable targeting specific cells in
attempts to repair injured tissue.
Plant vesicles
The project of Dr. Zhang and colleagues was to evaluate
exosome-like nanoparticles for therapeutic delivery of
RNAs. The existence and role of plant vesicles has been
generally under appreciated. Plant cells release vesicles
that contain proteins, lipids and RNAs (9,10). Their size
distribution ranges from 100 to 400 nm in diameter with a
negative zeta potential ranging from 49.2 to 1.52 mV;
their content varies with origin. These exosome-like nano-
particles are highly resistant to gastric pepsin solution
and to intestinal pancreatic and bile extract solutions,
thus indicating their potential for influencing cell biology
through ingested foods (10,11). Edible plant exosome-like
nanoparticles can be taken up by intestinal macrophages
and stem cells, thus preventing dextran sulphate sodium-
induced mouse colitis (9,10). These effects may be crucial
for maintaining intestinal homeostasis and gut immune
tolerance. The specific project here is to develop fruit
exosome-like vectors for multi-modal strategies to deliver
miRNA in a tissue-specific manner. Developing thera-
peutic agents must consider issues of targeting delivery,
safety and the cost of large-scale production. Dr Zhang
has developed a grapefruit-derived nano-vector to meet
all these requirements for safety, targeting and delivery
(12,13). Recently, the data generated from clinical trials
also support the concept that oral administration of grape-
exosome-like nanoparticle is potentially an effective and
safe treatment that may prevent the progression of head/
neck cancer (this data not published, but web link for the
trial is www.clinicaltrials.gov/ct2/show/NCT01668849).
Reversal of renal damage by mesenchymal
stem cell-derived vesicles
Mesenchymal stem cells (MSCs) are multipotent adult
stem cells which have immunomodulatory properties
(14), the capacity to differentiate into multilineage cells
of mesenchymal origin (15) and to migrate to the site of
an injury (16). MSCs have been shown to have reparative
effects in many settings. Clinical trials involving MSCs
include cardiovascular diseases, bone and cartilage de-
fects, spinal cord injury, graft-versus-host disease, Crohn’s
disease, diabetes and acute kidney injury (17). MSCs
can have curative effects in models of kidney injury and
detailed studies indicate that vesicles from the bone
marrow-derived MSCs mediate the observed healing
effects (18). The bone marrow-derived MSC EVs in these
studies were in the nano-range (60170 nm) and ex-
pressed specific markers of mesenchymal lineage (CD105,
CD73, CD44 and CD29) and of exosomes (LAMP-1,
CD63). MSC-derived EVs intravenously injected into
mice selectively localized to injured kidneys (19). Further
experiments on CD29 integrin and CD44 blockade in-
dicated that they were involved in vesicle uptake by
tubular cells (18). The MSC-derived vesicles translocated
to transcription regulator tubular epithelial cells, which
promoted downregulation of genes involved in cell apo-
ptosis (CASP1, CASP8 and LTA) and upregulation of
anti-apoptotic genes (BCL-XL, BCL2, and BIRC8) (16)
indicating possible healing mechanisms for the injured
renal tissue. In addition, in a model of cisplatin-injured
murine renal tubular cells, MSC-derived EVs were shown
to facilitate the transfer of IGF-1R mRNA and to
induce expression of human IGF-1R (20). This factor
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was shown to promote tubular cell proliferation by
increasing cell sensitivity to IGF-1. Human umbilical
MSC-derived EVs were also shown to be beneficial in
cisplatin-induced acute kidney injury by activation of the
extracellular-signal-regulated kinase (ERK) 1/2 pathway,
which is involved in tubular cell proliferation and pro-
tection from apoptosis (21). Moreover, in a chronic
mouse model of renal disease EVs released by MSCs
were shown to prevent fibrosis (22). Based upon studies
of RNase sensitivity and on the effects of Drosha knock-
down in vesicle originator cells (23), it was suggested that
the observed healing effects were mediated by miRNA
species. Elucidation of the miRNA targets is ongoing. In
vitro studies on renal tubular epithelial cells exposed to
ischemia-reperfusion injury induced by ATP depletion
showed a modulation of miRNA expression by MSC-
derived EVs partly due to miRNA transfer via EVs, and
partly to EV-triggered transcription (24).
Pulmonary hypertension and extracellular
vesicles
Pulmonary hypertension is a syndrome characterized by
vascular remodelling and right ventricular hypertrophy
and is associated with many different diseases. It is
treatable but not curable and it is eventually fatal. Its
aetiology is unknown. Aliotta and colleagues have been
evaluating a murine model of pulmonary hypertension:
the monocrotaline-treated mouse. They have found that
vesicles isolated from the plasma or lungs of these mice
induce pulmonary hypertension when infused into normal
mice (25). Moreover, bone marrow cells from the hyper-
tensive mouse when infused into irradiated mice induced
pulmonary hypertension. Most recently, they have shown
that lung-derived vesicles traffic to bone marrow induce
‘‘toxic’’ endothelial progenitors, which then have the capa-
city to induce pulmonary hypertension in normal mice.
Thus, we have initial insights into cellular mechanisms
underlying this disease.
In separate studies, the Aliotta group has found that
vesicles from bone marrow-derived MSCs can both pre-
vent and reverse the development of pulmonary hyper-
tension in the monocrotaline mouse model. This suggests
that MSC vesicles may have a role in treating pulmonary
hypertension. Further studies suggest that the ‘‘good’’
vesicles from bone marrow-derived MSCs alter the pheno-
type of the ‘‘toxic’’ vesicles back to normal.
MSC reversal of radiation-induced marrow stem
cell injury
Radiation exposure results in different levels of tissue
injury depending on dose, including the immune system,
the hematopoietic system, gastrointestinal tract, kidney,
skin and lung (26,27). Hematopoietic cells are sensitive to
radiation and exposure can result in bone marrow failure
and potentially lethal haemorrhage or infections. Six
months after exposure to 100cGy whole-body irradiation,
the engraftment capacity of murine marrow is reduced
to 20% of the non-irradiated control bone marrow (28).
A number of radiation mitigators have been described
which improve hematopoietic recovery from irradiation
damage. The transplantation of bone marrow can restore
haematopoiesis in lethally irradiated subjects (2931).
However, aside from transplantation, the efficacy of
these treatments is relatively limited and temporally
constrained.
The MSC is a cell population with multipotential and
plays a critical role in microenvironmental support of
the hematopoietic stem cell (15,32,33). The capacity of
MSCs for tissue repair has been reported in past decades.
The protective mechanisms are believed to be related to
either their differentiation capacity or to paracrine effects
(34,35). Transplantation of MSCs alone or with hemato-
poietic stem cells has also been shown to enhance engraf-
tment and improve bone marrow recovery from radiation
injury (3641).
Recent studies have shown that MSC-derived vesicles
mediate reversal of different tissue injuries to kidney, brain
and myocardium (18,22,4244). In this study, Quesenberry
and colleagues evaluated whether bone marrow MSC-
derived vesicles could reverse irradiation damage to bone
marrow stem/progenitor cells.
In our project, we have evaluated the capacity of
bone marrow-derived MSC vesicles to mitigate radiation
injury to bone marrow stem cells at 4 hours to 7 days after
irradiation. Significant restoration of bone marrow cell
engraftment at 4, 24 and 168 hours post-irradiation by
exposure to MSC-EV was evaluated at 3 weeks to 9
months after transplant and further confirmed by second-
ary engraftment. The Quesenberry group demonstrated
the recovery of peripheral blood counts and restoration of
the engraftment of bone marrow by intravenously injected
MSC-EV to 500 cGy exposed mice. Moreover, a reversal of
irradiation-induced gene expression was seen in peripheral
blood and bone marrow after treatment with MSC-EV.
The murine hematopoietic cell line, FDC-P1 exposed to
500cGy, showed dramatic reversal of growth inhibition
and apoptosis on exposure to murine or human MSC-EV.
In addition, a preparation with both exosomes and micro-
vesicles was found to be superior to either microvesicles or
exosomes alone. In addition, we have shown that both
murine- and human-derived vesicles are active against
irradiated murine bone marrow cells, that vesicles from
fresh bone marrow cells are active, and that MSC vesicles
stimulate normal murine marrow stem cell/progenitors to
proliferate. These studies indicate that MSC-EV have the
capacity to reverse radiation damage to bone marrow stem
cells and may represent an important new strategy in
radiation mitigation (45).
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Engineering exosomes as therapeutics for brain
disease
Though treatments for central nervous system (CNS) dis-
orders are being rapidly developed, their delivery across
the blood-brain barrier remains a significant hurdle.
Exosomes can easily cross the bloodbrain barrier with-
out use of an additive vehicle (46). Indeed, a variety of
administration routes successfully deliver exosomes to the
CNS (4648). This suggests that exosomes can be loaded
with drugs for CNS delivery, and there is significant
interest in exploiting exosomes by re-engineering them
as immunomodulators or delivery platforms for cancer
therapeutics (49) and vaccines (50). However, Richard
Kraig and colleagues find that some exosomes are
therapeutic in and of themselves.
The Kraig lab studied exosomes as a means of im-
proving recovery from demyelination in multiple sclerosis
(MS), an inflammatory disease involving oligodendrocyte
loss, demyelination and failure to repair damaged myelin
(46). Most current MS therapeutics reduce demyelination
via immune suppression, and thus often produce harmful
immune sequelae. No existing therapies treat progres-
sive MS, and though some may aid remyelination, none
extensively regenerate myelin.
The Kraig group found that exosomes derived from
the serum of rats exposed to environmental enrichment
(EE; volitionally increased physical, intellectual and
social activity) improved recovery from lysolecithin-
induced demyelination in an in vitro model of MS (51).
Furthermore, nasal administration of these exosomes to
naı¨ve rats increased CNS myelin, oligodendrocyte pre-
cursor and neural stem cell levels, and reduced oxidative
stress. They found that these exosomes contained high
levels of miR-219, a microRNA that is crucial for oligo-
dendrocyte maturation and the formation and mainte-
nance of compact myelin (52,53).
To mimic EE and create a scalable source of ther-
apeutic exosomes, we stimulated primary dendritic cell
cultures (DCs) with IFNg, a pro-inflammatory cytokine
that is physiologically increased during EE. Exosomes
produced by IFNg-stimulated DCs (IFNg-DC-Exos)
increased myelination and oxidative tolerance in vitro
and in vivo. These IFNg-DC-Exos also contained high
concentrations of miR-219, increased oligodendrocyte
precursor differentiation and improved recovery from ex-
perimental demyelination (46). Future steps toward ther-
apeutic use of DC exosomes may include re-engineering
them to contain only specific microRNAs, or altering
their surface composition to target-specific cell types.
Production of extracellular vesicles in good
manufacturing production
This work approaches what is necessary for the GMP
production of vesicles for eventual clinical trials. The re-
quirements include isolation approaches, quantification
of vesicles, potency determination, characterization of cell
source, analysis of contents and surface epitopes of vesicles.
Toxicity studies will be necessary along with evaluation of
dose responses, time courses and vesicle stability (5456).
Biologic evaluations will be necessary during different
phases of GMP process including production, recovery,
characterization and storage. Regulations in Europe and
the US will have to be rigorously followed. The regula-
tory considerations would take into account those for
the cells of origin. In the case of MSCs, clear criteria of
identity and biosafety are available. The challenge is to
define criteria for EVs taking into account the following
considerations. The available preparative methods result
in a heterogeneous population of EVs. Further separa-
tion to a homogenous population would not be techni-
cally possible in a GMP condition that requires minimal
manipulation, because there are not definite size, density
or protein markers that can reliably define a specific
population. Therefore, EV product should not have an
absolute requirement for characterization of cell surface
markers, content or for homogeneity but rather should be
based on the definition and description of a size-defined
(nanosize range), functionally effective population isolated
using a robust, reproducible and validated process. The
safety efficacy profile as well as bio-distribution needs
to be demonstrated in preclinical studies. Valuation of
efficacy should rely on functional potency tests relevant
to the proposed application. Finally, the dose and the
route of administration should be defined on the basis of
efficacy and safety profiles, bioavailability and specific
formulation of the therapeutic product, for example, the
EV product may be cryopreserved, lyophilized, used in
cell suspension or combined into a matrix.
Retroviral-like particles
There is a common consent in the field that EVs are
composed of a variety of vesicles that vary in diameter,
content, membrane composition and biogenesis. So far,
we lack a clear understanding of the biology behind these
subpopulations which results in the lack of methods to
efficiently separate and study these vesicles. EV subpopu-
lations addressed in different studies include exosomes,
oncosomes, microparticles and retroviral-like particles.
The latter is the focus of this section. Retroviral-like
particles relate to remnants of ancestral infections by
active retroviruses of germ lines in primates, which have
been thereafter transmitted to the progenies (57). These
sequences comprise about 8% of the human genome and
are mostly silent due to methylation, recombination or
mutations in either the long terminal repeats (LTRs),
gag, pol, env or prt genes. Defects in either of these
proteins, which are necessary for assembly of infectious
viral particles, result in the production of defective retro-
viral particles. Thus, endogenous retroviruses can produce
particles that resemble proviruses of true retroviruses
Peter J. Quesenberry et al.
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composition and, under normal conditions, can move
only within cells (57). DNA hypomethylation is a com-
mon phenomenon in all cancer types, and probably due to
their abundance, repetitive elements seem mostly affected
by this change (58). This results in many of the endogen-
ous retroviral sequences becoming transcriptionally ac-
tive, with the increased chance of forming retroviral-like
particles that can end up in the intercellular space and
biofluids. In fact, retroviral-like particles have been isolated
from the plasma of patients with lymphoma and breast
cancer, as well as of HIV patients (59,60). In the context of
EVs, several studies have reported the presence of non-
coding RNA species in EVs (61), and particularly a signi-
ficant enrichment of human endogenous retroviral (HERV)
sequences from glioblastomas, suggesting a common bio-
genesis pathway between EVs and retroviral-like particles,
where retroviral RNA is specifically packaged into vesicles
(62,63). Furthermore, HERV sequences were shown to
be transferred from normal medulloblastoma cells to
human endothelial cells (HUVECs) and remained high up
to 72 hours, suggesting that tumour cells can specifically
package HERV RNA into particles that can be sent out
to neighbouring cells to modify their phenotype and
genotype. Other studies also indicate that cells produce
a highly specified type of vesicles upon infection or ex-
posure to other stimuli (64,65). Clearly, EVs share path-
ways with the assembly machinery of several other viruses,
including HERVs, and this convergence may explain the
observation of viral-like particles containing viral proteins
and nucleic acid in EVs. In particular, tumour cells may
be exploiting remnants of the retroviral-like packaging
machinery for its own advantage to ‘‘infect’’ surrounding
normal (or distant) cells and spread malignancy.
Extracellular vesicles in cancer
Extracellular vesicles in prostate cancer progression
As carriers of genomic and oncogenic factors, tumour-
derived exosomes have been implicated in genetic ex-
change with non-malignant cells (66). The current evidence
lends credence that exosomes are involved in commu-
nication and intercellular trafficking of bioactive mole-
cules between tumour cells and MSCs. Abdel Mageed
et al. recently showed that prostate cancer (PC) cell-
derived exosomes were capable of recruiting PC patient-
derived adipose stem cells to the tumour sites in vivo (67).
Once engrafted, these cells underwent prostate tumour
mimicry by expressing PC-specific markers. The ex-vivo
treatment of patient-derived adipose stem cells by PC
cell-derived exosomes triggered neoplastic reprogram-
ming of these cells upon transplantation into immuno-
compromised mice. Consistent with our findings, exosomes
derived from bone marrow mesenchymal stromal cells
(BM-MSCs) were reported to support multiple myeloma
(MM) clonal expansion and promote MM formation
in vivo (68). Ovarian and breast cancer-derived exosomes
render adipose tissue-derived MSCs to undergo physical
and functional characteristics suggestive of phenotypic
transformation into tumour-supporting myofibroblasts
in tumour stroma (69,70). In addition, cancer cells are
induced to exhibit epithelial-to-mesenchymal transition
(EMT) phenotype upon release of the epidermal growth
factor receptor (EGFR) and tissue factor (TF)-containing
exosomes (71). The TF-containing exosomes are cap-
able of enhancing the procoagulant activity of endothelial
cells  thus influencing tumour-vascular interactions (71).
The final message here is that PC exosomes potentially
aid aggressive epithelial cancer cells to exhibit mesench-
ymal characteristics and to adopt aberrant interactions
with other cells at tumour sites. Conversely, in the present
work, we have shown that MSC or normal PC-derived vesi-
cles can reverse chemoresistance or anchorage-independent
growth in vitro and the neoplastic phenotype in vivo in
rodent models.
Although the underlying mechanisms remain elusive,
tumour cell vesiculation has been implicated in cancer
progression by promoting angiogenesis growth and
metastasis (72,73) In addition, the tumour-associated
exosomes aid cancer progression by suppressing the
immune system (74,75).
Lundholm et al. (76) recently demonstrated that the ex-
pression of NKG2D ligand by PC cell-derived exosomes
contributes to PC progression through downregulation
of its cognate activating cytotoxicity receptor NKG2D
on natural killer (NK) and CD8 T cells in a dose-
dependent manner. The circulating NK and CD8 T cells
in colorectal and prostate cancer (CRPC) patients have
significantly lower levels of surface NKG2D expression,
compared to healthy subjects. Interestingly, circulating
exosomes from CRPC patients suppress NKG2D expres-
sion in effector lymphocytes  thus promoting tumour
escape and disease progression (76). The loss frequency of
cytoskeletal regulator DIAPH3 is significantly higher in
advanced PC and is associated with transformation into
an amoeboid phenotype marked by enhanced tumour
cell migration, invasion and metastasis (77). Silencing of
DIAPH3 triggers EVrelease by PC, which in turn activates
Protein kinase B (AKT) and suppresses tumour-infiltrating
immune cells (77). Collectively, the aforementioned find-
ings attest to the emerging mechanistic role of EVs in PC
progression. Targeting EV biogenesis and release by PC cells
and/or their uptake by recipient cells may have preventive
and therapeutic benefits for patients with advanced PC.
Extracellular vesicles in colorectal cancer
All cancers, including colorectal cancer (CRC), are
characterized by driver mutations that allow their growth
free of mitigating regulatory signals in their local cellular
environment leading to tumour growth and metastasis.
Most sporadic CRCs have mutations that activate
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canonical WNT signalling, and most of these mutations
are in adenomatosis polyposis coli (APC) (78). Such
tumours incur activating mutations in oncogenes such as
the small GTPase KRAS, mutated in 3040% of CRC
and PI3-Kinase, while other mutations occur in tumour
suppressive genes like TP53 as well as TGFß pathway
members like TGFßRII receptor and SMAD4. These
mutational events, along with amplifications, deletions
and translocations, are associated with neoplastic pro-
gression. Much of the work on such driver mutations
concerns their regulation of cell autonomous effects
within mutant-containing epithelial cells, but non-cell
autonomous effects that pattern the tumour microenvir-
onment can be mediated by EVs. EVs include the smaller
40150 nm endosomally derived exosomes and the larger
cell-membrane-budded microvesicles (MVs) that reach an
upper limit of about 1 mm. How oncogenic mutations in
tumour cells alter EVs and how these altered EVs change
the tumour microenvironment is an important new area
of study. Here, we review the status of EVs in CRC. An
important issue in the field is the heterogeneity of vesicles
secreted from cells. It has been shown that such secreted
vesicles carry both activated receptors and ligands that
can signal to recipient cells, inducing cell growth and
invasive properties (79) and also carry oncogenes, tumour
suppressors and even RNAs that regulate tumour growth.
Two strategies have been used to address how tumour
progression might alter the functional non-cell autono-
mous EVs output; one tests how the presence or absence
of oncogenes or tumour suppressors alters the constitu-
ents of EVs; the other is to use the degree of transforma-
tion of model cells to provide a template to compare
subsets of EVs. Some of the cell models used to test some
of these questions are shown in Table I. EVs from
different sources are added to recipient cells to test their
growth-altering function. The composition and function
of such EVs depends on how they are purified and
sub grouped. These differences have implications for the
potential biomarker properties of such EVs.
Several groups have performed comprehensive proteo-
mic analysis of EVs from various cell line-derived (see
Table I) or in vivo EVs (83,87,93). The different methods
used to purify such vesicles (94) range from standard differ-
ential centrifugation alone (81,82), iodixanol [OptiPrepTM]
gradient and/or sucrose gradient (83,84,86,87,95), immu-
noaffinity isolation (86,87,96), FPLC purification (97)
and flow sorting of vesicles (81,83,98). Certain core pro-
teins are observed repeatedly using all methods, enriched
to varying degrees; such enriched proteins include multi-
ple tetraspanins like CD81 and CD9, as well as multi-
vesicular body (MVB) biogenic proteins like TSG101 and
ALIX (PDCD6IP) (99). Because ‘‘exosomal pellets’’
contain multiple other species (86), including free protein
complexes (100), depending on source, lipoprotein com-
plexes (97) and other vesicles of non-endosomal/MVB
origin, whether budded directly from the plasma mem-
brane (101) or derived from other organelles (91), the
choice of purification method used in the above studies
has affected which proteins are identified and influences
what is termed EV-associated generally or exosome-
associated specifically.
For example, LIM1863 cells, which polarize as sus-
pended cysts in media, do not attach to plastic and
produce differentiated enterocytes, and goblet cells
were used to isolate distinct A33-containing or EpCAM-
containing exosomes (96). Proteomic analysis of immune-
captured A33 exosomes shows they contain basolateral
cargo and specific trafficking proteins, many of which
are basolateral trafficking proteins. EpCAM is an apical
tight junction protein in LIM1863 cells; immune capture
with EpCAM yielded apical proteins within the captured
exosomes. These results show there are at least 2 distinct
vesicle populations associated with these cells, derived
potentially from 2 different cellular membranes.
Several groups have used SW480 cells derived from a
primary CRC tumour and SW620 cells derived from a
lymph node metastasis from the same patient to compare
metastatic protein changes that occur in EVs derived
from these related cell lines. These studies (83,84) show
that metastatic markers are upregulated in SW620 com-
pared to SW480 EVs, finding upregulation of MET as
well as lipid raft components CAV1, FLOT1 and 2,
PROM1 (CD133) and tyrosine-protein kinase Src (SRC)
up in SW620 exosomes (84), while EGFR was up in SW480
exosomes. It was also found that the TNIK-RAP2a
complex is unique to SW620 exosomes, which has
Table I. CRC cell lines and characteristics
DLD-1, DKO-1,
DKS-8
Parental DLD-1: APC mutation KRA S /G13D, DKs-8 [/ with decreased transformed
characteristics and DKO-1 (G13D) (8082)
SW480, SW620 SW480 and SW620 established from a single individuals primary cancer and lymph node metastasis,
respectively. Both have a mutant KRAS (G12V) and an APC mutation
(83, 84)
LIM1863 Forms cysts in suspension with polarized cells; contains colonocytes and goblet cells (85, 86)
LIM1215 Non-polyposis CRC cell line, MSI cancer (85, 8789)
HT29 Mutant APC, mutant BRAF, polarizing cell line (90)
HCT116 b-catenin mutation and heterozygous for KRAS (G13D/ ), wild-type P53 (91)
Caco-2 Mutant APC polarizing cell line (92)
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implications for the invasive potential of such exosomes.
EVs from these cells were also compared to other CRC
cell lines LIM1215, HT29 as well as CRC ascites, which
identified other co-expressed and different EV markers
(83). In a separate study, it was shown that restoration of
wild-type APC expression to SW480 cells leads to
induction of the WNT inhibitor DKK4 in the cells and
their exosomes, which suggests APC may also regulate
WNT signalling non-cell autonomously through DKK4
secretion in exosomes.
How the presence or absence of mutant KRAS alters
the proteins and function of exosomes was tested with
the DLD-1 parent cell line that is heterozygous for
KRAS, having one mutant activated allele and one
wild-type allele. Isogenic cell lines were created from
DLD-1, selectively knocking out the wild-type (DKO-1)
or mutant KRAS allele (DKs-8) (78). A comprehensive
proteomic analysis of these exosomes showed that, de-
pending on cell source, they contained very different
constituents, with mutant KRAS cell-derived exosomes
having increased levels of SRC, EGFR and mutant
KRAS compared to exosomes from wild-type KRAS
DKs-8 cells (82). Functional studies showed that mutant
KRAS-containing DKO-1 exosomes could transfer the
mutant KRAS protein to wild-type KRAS-expressing
cells, thereby demonstrating non-cell autonomous trans-
fer of an oncogene. Such mutant KRAS exosomes could
also induce cell growth and invasive characteristics in
these recipient cells. It was also shown that DKs-8
exosomes contained many more RNA binding proteins
than those derived from DKO-1 cells, which has implica-
tions for these exosomes as RNA carriers.
It was shown that exosomes released by mutant
KRAS cells contain increased levels of the EGFR ligand,
amphiregulin (AREG) (81). EGFR ligands are trans-
membrane proteins that can act as secreted factors when
they are cleaved from the cell surface via metalloproteases;
it was demonstrated that EGFR ligands AREG, trans-
forming growth factor alpha (TGFA) and heparin binding
EGF like growth factor (HBEGF) are maintained as
intact transmembrane proteins within exosomes (81). In
separate experiments, individual EGFR ligands were
tested for their ability to induce invasive characteristics
in recipient cells (81). It was shown that exosomal AREG
significantly enhanced the invasive capacity of recipient
breast cancer cells compared to secreted soluble AREG
or other EGFR ligands, whether these ligands were
in exosomes or soluble. The invasive effect of AREG
exosomes was, at least in part, due to recipient cell EGFR.
Using fluorescence-activated vesicle sorting (FAVS), a
flow cytometric method for analyzing and purifying
exosomes (81,98,101), it was shown that DLD-1 cells
secreted a complex mixture of exosomes that carried
varying levels of the EGFR ligands HBEGF, AREG and
TGFA that fell into at least 9 classes of distinct exosomes.
These results show that the exosomal composition from
these cells is complex and that proteomic analysis of
such exosomes identifies proteins in multiple subgroups of
exosomes present in these preparations.
In other work using HCT-116 cells, mutant KRAS
was shown to induce P53 secretion from a clearly non-
exosomal vesicular component (91). Here, P53 is secreted
from mutant KRAS-expressing cells through binding to
the EMT-associated transcription factor SNAIL (which
is co-secreted) and a P53 nuclear export sequence muta-
tion does not inhibit this process, suggesting that such
P53 export is derived from a nuclear subcompartment.
Consistent with this finding, P53 vesicular structures were
surrounded by nuclear membrane component, and ex-
port occurs through a vesicle-like transport mechanism
requiring cytoskeleton function. Mutant KRAS induces
CAV1, and results suggest CAV1 regulated endocytosis is
responsible for P53 uptake from the media. Autoantibo-
dies to SNAIL were found in cancer patient sera, which
may be a potential biomarker for CRC. These results
show complex functions for mutant KRAS-induced
changes in secreted factors, leading to the export and
uptake of the P53 tumour suppressor and the EMT
inducer, SNAIL. The pace of cancer related findings con-
tinues to accelerate.
EVs in cardiovascular diseases
Functional role for EVs in the cardiovascular system
Cardiomyocytes (CMs), cardiac fibroblasts, endothelial
and cardiac progenitor cells have all been shown to
secrete EVs (102,103). Like EVs from other cell types,
they contain a variety of proteins and RNAs from the
parent cell and appear to have functional effects on
neighbouring cells.
CM- and fibroblast-derived EVs
EV release from CMs was first reported by Gupta and
Knowlton in primary cultures of adult rat CMs, and
appeared to be regulated by hypoxia (104). In a second
study, hypoxia led to the release of the 26 kDa transmem-
brane form of TNF-a in CD63 EVs. Exposure of
healthy CMs to these EVs induced apoptosis, suggesting
that stress may lead to deleterious signalling between CMs
(105). A recent study also demonstrated the transfer of
DNA and RNA from CMs to fibroblasts (102). EVs
released by HL-1 cells were found to contain DNA and
RNA, as labelled with acridine orange, and when added to
NIH-3T3 cultures, could transfer the acridine orange
staining into NIH-3T3 fibroblasts nuclei, thereby demon-
strating EV-mediated transfer of genetic information from
CMs to fibroblasts. Cargo present within the EVs
included ribosomal RNA and mRNA coding for proteins,
and transfer of this produced changes in gene expression
within the fibroblasts. Our own recent work demonstrates
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clear uptake of EVs derived from primary neonatal rat
CM cultures into cardiac fibroblasts (Fig. 1), suggesting
that EVs may indeed be an important mode of paracrine
signalling among cells of the cardiovascular system.
Interestingly, a recent study demonstrated that cardiac
fibroblast-derived EVs also transfer information to CMs
(103). Cardiac fibroblast-derived EVs contained many
passenger strand miRNAs that are normally subjected
to intracellular degradation. These miRNAs were shown
to be potent pro-hypertrophic factors in the CMs,
and inhibition of one of these, miR-21-3p, attenuated
pathology (Fig. 1).
In the present work, using a unique mouse model of
genetic fluorescent labelling of different cell types, the
Das laboratory has been assessing the contribution of
circulating EVs in murine models of heart disease. The
profile and content of EVs in human heart disease is
being simultaneously addressed. Functionality of EVs
derived from the heart: using EVs isolated from human
heart failure patients, control patients or post-myocardial
infarction patients, the Das laboratory is assessing their
role in altering gene expression and function in human
iPSC-derived CMs and fibroblasts. Together these experi-
ments are expected to provide a more detailed character-
ization of the origin and function of heart-derived EVs.
Conclusions
This represents work by individuals in initiative 4 on
clinical utility of exRNAs as therapeutic agents and
developing scalable technologies required for these stu-
dies within the NIH Extracellular RNA Communication
Program. It also includes selected work by collaborators.
The work on plant EVs is quite unique and represents an
area of investigation which will be rapidly expanding and
could be a major factor in eventual clinical applications.
The studies on repair of renal, bone marrow, cardiac,
pulmonary and neural tissues highlight the whole area of
vesicle potential in regenerative medicine, which con-
tinues to expand. The role of retroviral-like particles in
EVs is of intense interest and raises some concern. The
role of EVs in cancer is also of intense interest. Here,
there is evidence for ‘‘good’’ and ‘‘bad’’ vesicles. The
‘‘good’’ may be derived from normal tissue or mesenchymal
stem cells and can reverse malignant phenotypes while
the ‘‘bad’’ derive from neoplastic cells and can progress a
malignant phenotype. In a similar fashion, there are both
‘‘good’’ and ‘‘bad’’ vesicles in pulmonary and cardiovas-
cular diseases. These observations illustrate the basic
heterogeneity of EVs from different tissues under differ-
ent separative approaches and subjected to various
stimuli. Further, heterogeneity rests in the nature and
condition of vesicle target cells. This heterogeneity is a
critical consideration as to eventual production of EVs
in good manufacturing production. The field is moving
rapidly toward a variety of therapeutic strategies with
clinical protocols already evolving.
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